Literature DB >> 15362793

Survival of gastric cancer with concomitant liver metastases.

Ching-Ming Kwok1, Chew-Wun Wu, Su-Shun Lo, King-Han Shen, Mao-Chih Hsieh, Wing-Yiu Lui.   

Abstract

BACKGROUND/AIMS: Prognosis of gastric cancer with concomitant liver metastasis is poor. Gastrectomy and chemotherapy had been reported to be beneficial to this group of patients. Whether all the patients can benefit from that treatment modality and whether the clinical characteristics can give some information about survival have not been evaluated.
METHODOLOGY: Eighty-three gastric cancer patients with concomitant liver metastases who had received treatment in the past 10 years were retrospectively studied with special reference to different extent of liver metastases. Clinical characteristics (peritoneal tumor dissemination, tumor markers, clinicopathological factors), treatment modalities (gastrectomy or chemotherapy) and survival were analyzed for their possible relationship with the extent of liver metastases.
RESULTS: There were 33 patients with liver metastases limited to one lobe and 50 patients had metastases in both lobes. The clinicopathological characteristics show no difference between uni- and bilobar liver metastases except higher percentage of concomitant peritoneal dissemination in patients with bilobar disease. More unilobar involvement patients underwent gastrectomy (70% vs. 48%, p=0.018). Higher frequency of abnormal CEA level in bilobar metastases (38% vs. 60%, p=0.045). Median survival of unilobar metastasis is 7.8 months and 4.3 months for the bilobar involvement (p=0.001). Gastrectomy might prolong the survival in patients with unilobar metastasis (p=0.005), but not in patients with bilobar diseases (p=0.074). Chemotherapy could prolong the survival in patients without gastrectomy, but not the survival after gastrectomy.
CONCLUSIONS: The clinicopathological characteristics and tumor markers have no role in predicting the survival among patients with liver metastases. Both gastrectomy and chemotherapy for the patients without gastrectomy could prolong survival, but chemotherapy could not prolong the survival after gastrectomy, the benefit of resection and chemotherapy are probably caused by selection bias.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15362793

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  6 in total

Review 1.  Role of periostin and its antagonist PNDA-3 in gastric cancer metastasis.

Authors:  Guo-Xiao Liu; Hong-Qing Xi; Xiao-Yan Sun; Bo Wei
Journal:  World J Gastroenterol       Date:  2015-03-07       Impact factor: 5.742

2.  Surgical treatment of liver metastases of gastric cancer: is local treatment in a systemic disease worthwhile?

Authors:  Mattia Garancini; Fabio Uggeri; Luca Degrate; Luca Nespoli; Luca Gianotti; Angelo Nespoli; Franco Uggeri; Fabrizio Romano
Journal:  HPB (Oxford)       Date:  2012-03       Impact factor: 3.647

3.  The value of resection of primary tumor in gastric cancer patients with liver metastasis.

Authors:  Sevim Turanli
Journal:  Indian J Surg       Date:  2010-08-26       Impact factor: 0.656

4.  Radiofrequency ablation for treating liver metastases from a non-colorectal origin.

Authors:  Bo La Yun; Jeong Min Lee; Ji Hyun Baek; Se Hyung Kim; Jae Young Lee; Joon Koo Han; Byung Ihn Choi
Journal:  Korean J Radiol       Date:  2011-08-24       Impact factor: 3.500

Review 5.  Surgical treatment of liver metastases of gastric cancer: state of the art.

Authors:  Fabrizio Romano; Mattia Garancini; Fabio Uggeri; Luca Degrate; Luca Nespoli; Luca Gianotti; Angelo Nespoli; Franco Uggeri
Journal:  World J Surg Oncol       Date:  2012-08-03       Impact factor: 2.754

6.  Comparison of Therapeutic Efficacy between Gastrectomy with Transarterial Chemoembolization Plus Systemic Chemotherapy and Systemic Chemotherapy Alone in Gastric Cancer with Synchronous Liver Metastasis.

Authors:  Sen-Feng Liu; Can-Rong Lu; Hai-Dong Cheng; Hong-Qing Xi; Jian-Xin Cui; Ji-Yang Li; Wei-Song Shen; Lin Chen
Journal:  Chin Med J (Engl)       Date:  2015-08-20       Impact factor: 2.628

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.